Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Recurrent High-Grade Gliomas, Malignant Gliomas
Interventions: Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Glipizide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: High Risk Pregnancy
Interventions: Relaxation Intervention; Behavioral
Lead sponsor: Towson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Adenomatous Polyp, Colorectal Cancer, Obesity
Interventions: metformin hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Long Beach, California • Orange, California • Sacramento, California

Conditions: Dysplasia, Cancer
Interventions: Luma Cervical Imaging System; Device
Lead sponsor: SpectraScience; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Encinitas, California • Iowa City, Iowa

Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Social Anxiety Disorder, Sleep Laboratory
Interventions: Sleep-enhancement of extinction memory; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlestown, Massachusetts

Conditions: Carcinoma, Squamous Cell
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 30
States / cities: Mobile, Alabama • Duarte, California • La Jolla, California + 26 more

Conditions: Physical Fitness
Interventions: Supra high intensity interval training; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Placebo, AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Inglewood, California • Northridge, California • Pomona, California + 20 more

Conditions: Physician-Patient Relations, Inpatient Facility Diagnoses, Electronic Health Records, Outpatient
Interventions: High Touch, Low Touch, High Tech, Low Tech; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 3,782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Interventions: Screening Method (SM), Screening and Communication Method (SCM); Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 12 Years to 30 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab; Biological · Procedure · Radiation
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 4
States / cities: Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more

Conditions: Down Syndrome, Fetal Aneuploidy
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Mobile, Alabama • Tucson, Arizona • Campbell, California + 24 more

Conditions: Cardiac Surgery
Interventions: teprasiran, Placebo; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more

Conditions: Arthropathy of Knee, Arthritis and/or Post-traumatic Degenerative Problems
Interventions: Optetrak PS, Optetrak Hi-Flex; Device
Lead sponsor: Exactech; Industry
Eligibility: 50 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Newport News, Virginia

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neuroblastoma
Interventions: GM-CSF + Naxitamab; Biological
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more

Conditions: Breast Cancer
Interventions: Dedicated breast CT(BCT); Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Central Nervous System Neoplasms, Medulloblastoma
Interventions: Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging Testing, Echocardiography Test, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cardiovascular Risk Factor
Interventions: High Salt, Recommended Salt; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Substance Abuse
Interventions: cognitive behavioral training; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Search by objective public record fields.

Bevacizumab for Recurrent Malignant Glioma

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Relaxation Interventions for Pre-term Mothers on Hospitalized Bed-Rest

Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI

Study of LUMA Cervical Imaging System as Adjunct to Colposcopy

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Supra High-intensity Interval Training for Police Officers

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

High Tech and High Touch (HT2): Transforming Patient Engagement Through Portal Technology at the Bedside

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Optetrak Posterior Stabilized Versus Optetrak Hi-Flex

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

The Salty Gut: Effects of High Dietary Salt Intake on the Gut Microbiota

Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy